1 / 70

Sex & Gender in Acute Care Medicine

Sex & Gender in Acute Care Medicine. Chapter 5: Sex, Drugs, and Toxicology. Annette Lopez Robert G. Hendrickson. Case Study. A 30-year-old female presented via EMS after being involved in a single-vehicle crash

olwen
Télécharger la présentation

Sex & Gender in Acute Care Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Sex & Gender in Acute Care Medicine Chapter 5: Sex, Drugs, and Toxicology

  2. Chapter 5: Sex, Drugs, and Toxicology Annette Lopez Robert G. Hendrickson

  3. Case Study • A 30-year-old female presented via EMS after being involved in a single-vehicle crash • She was found by police, restrained, resting her head on the steering wheel with her car in a ditch • When awokened, she appeared to be in a dreamlike state • On arrival to the ED, she had normal vital signs

  4. Case Study • Patient was well-appearing but difficult to arouse • Exam revealed no signs of trauma • On arousal, patient had no recollection of the events leading to the collision • She recalled waking up, getting ready, and being on her way to work

  5. Case Study • Patient denied any drug or alcohol use the previous night • She was found to have a negative blood alcohol concentration and negative urine drug test • Prescription drug history was significant for use of zolpidem 10mg at bedtime

  6. Case Study • In January 2013, the FDA notified the public of concerns for next morning impairment after use of zolpidem • The agency was particularly concerned about slower elimination of the drug in women compared to men • This notice was followed in May 2013 by label changes to zolpidem dosing • New label dosing reduced the starting dose of the immediate-release formulation from 10mg to 5mg

  7. Introduction • Sex and gender influence the effects of pharmaceuticals on an individual, including: • drug dosing • rate of drug-drug interaction • the body’s ability to absorb, distribute, metabolize, and excrete medications • differences in time course and intensity of adverse effects

  8. Introduction • Women account for the majority of acute overdose ingestions • They also have a higher rate of adverse effects • Sex is also responsible for the generation of special populations, pregnant and breastfeeding women, in which drugs have unique effects • Unique effects have also been noted for women when exposed to certain medications related to chronic conditions such as HIV and cancer

  9. Introduction • Unfortunately, research on sex differences has only recently become a priority • The FDA issued the first guideline for the evaluation of sex differences in drug trials in 1993 • It allowed more women to be included in clinical trials, with further enforcements demanding equal participation in 1998

  10. Introduction • In 2004, the FDA produced a draft guideline addressing pharmacokinetics in pregnancy • Reviews of participation after these guidelines revealed increasing involvement of women • Yet continued underrepresentation in early phases of clinical trials • Concerns of teratogenicity are likely responsible • However, this goes against the current FDA recommendation

  11. A note on terminology • Sex and gender are commonly interchangeable terms • However, “sex” refers to the physiological differences between males and females that are most heavily influenced by hormones and anatomy

  12. A note on terminology • “Gender” is a societally ascribed term that reflects environmental, cultural, and behavioral differences • In this chapter, we will use the term “sex differences” given that the available pharmacologic data reflects mostly hormonal rather than environmental or behavioral differences

  13. Pharmacology • Sexual hormones can lead to direct and indirect effects on the pharmacology of drugs • Hormones can have direct effects on drug response • They can also lead to modifications in the intrinsic hormonal sequences

  14. Differential Drug Dosing • Although individuals vary, men and women differ significantly in body size and composition • In general, women have a higher percentage of body fat and lower total mass • Recommended drug dosages are currently calculated for the “average” 70 kg male • Single-dosing approach leads to the potential for higher concentrations and more adverse affects in women

  15. Drug-Drug Interactions • Drug-drug interactions are a major cause of morbidity • Perhaps the most common interaction for which the patient’s sex is a factor involves oral contraceptive pills (OCPs) • OCPs are the most commonly prescribed medications for women of reproductive age

  16. Drug-Drug Interactions • Studies researching drug metabolism of OCPs have generated mixed results with the metabolism of some drugs being inhibited, unaffected, or even enhanced • The combined use of anticonvulsants (e.g., carbamazepine) or anti-tuberculars with OCPs increases drug clearance and leads to decreased OCP serum concentrations with decreased efficacy

  17. Drug-Drug Interactions • Conversely, coadministration of antifungals or warfarin with OCPs may lead to decreased OCP clearance and increased OCP concentrations • OCP concentrations are also increased with antibacterials such as penicillin, ampicillin, tetracyclines, and cephalosporins due to inhibited enterohepatic recirculation

  18. Drug-Drug Interactions • OCPs may lead to alterations in the concentrations of coadministered drugs • In the presence of OCPs, benzodiazepines, clofibric acid, cyclosporin, phenytoin, rifampin, and warfarin demonstrate increased clearance, lower serum concentrations, and decreased efficacy

  19. Drug-Drug Interactions • Conversely, OCPs lead to decreased drug clearance of: • Imipramine • Amitriptyline • Caffeine • Corticosteroids • Selegiline • Theophylline

  20. Placebo Effect • May play an important role in therapeutic management and its effect may vary with sex • Studies on the efficacy of placebo have found women to be either less responsive or more responsive than men • Women report more side effects to medication than men with either active or inactive drugs • While men only report adverse effects with the active pharmaceutical

  21. Pharmacokinetics - Absorption • Pharmaceutical absorption may be somewhat slower in women than in men, although this effect is not consistently reported • Absorption of medications depends on multiple variables, some of which are dependent on drug characteristics • Others are due to the route of administration

  22. Absorption • Absorption depends on: • pH differences between the lumen the mucosa, • surface area of the pharmaceutical, • perfusion to the absorptive villi, • available digestive enzymes within bile, • and the integrity of the gastrointestinal epithelium

  23. Absorption • Women tend to have higher gastric pH levels, leading to rapid absorption of basic medications (e.g., benzodiazepines) • Women have less active gastric enzymes, which may lead to higher drug concentrations • For example, lower concentrations of gastric alcohol dehydrogenase in women leads to higher alcohol concentrations even after equivalent weight-based dosing

  24. Absorption • Men and women differ in regard to the composition of bile acids • This may explain differential absorption • Chenodeoxycholic acid, found in higher concentration in women than men, inhibits CYP450 enzymes involved in the metabolism of aniline, benzo(a)pyrene, 7-ethoxy-coumarin, p-nitroanisole, aminopyrine, and testosterone

  25. Absorption • In a review of bioequivalence studies submitted to the FDA from 1977-1995, the maximum concentration (Cmax) of medication in women was higher than in men 87% of the time • The area under the curve (AUC) for women was higher 75% of the time • Respiratory tract delivery of medications has also been found to be affected by sex differences

  26. Ethanol • Since antiquity, it has been known that women are more sensitive to the clinical effects of ethanol ingestion • Body mass is not the only factor • A 2001 study revealed that lower gastric alcohol dehydrogenase (ADH) activity plays a dominant role in the noted sex difference in alcohol metabolism

  27. Ethanol • Other contributors to the observed sex difference include lean body mass, gastric emptying, and hepatic oxidation • All of which are influenced by sex hormones, liver volume, ethnicity, and genetic polymorphisms of both ADH and aldehyde dehydrogenase

  28. Distribution • Distribution of a medication after absorption is best described by the volume of distribution • The theoretical body volume that would be occupied by the drug given the measured serum concentration • Volume of distribution depends on many factors: • Body mass, body fat composition, local perfusion, and protein binding • All of which differ between men and women

  29. Distribution • Women tend to have a lower body mass and blood volume compared to men • Given that adult drug dosing is generally not weight-based, the average women will have higher drug concentrations compared to the average man • The higher percentage of body fat found in women may lead to initially lower drug concentrations of lipid soluble compounds

  30. Distribution • However, this places women at risk for bioaccumulation within fatty tissue, leading to prolonged half-lives of elimination • For example, women who receive propofol infusions have lower serum concentrations and wake up faster than men given the same weight-based dose

  31. Distribution • Plasma protein binding is important in the determination of drug effects • Non-protein-bound (“free”) drugs are responsible for clinical effects • Drugs bound to protein cannot penetrate tissues or bind to receptor sites • Women have lower protein-binding capacity and, therefore, higher concentrations of free drug, which may contribute to adverse effects

  32. Metabolism • Medication metabolism involves many enzymatic processes • Sex differences are responsible for slower rates of both glucuronidation and hydrolyzation in women compared to men • These slower rates result in higher concentrations of active substances in women • Thus the potential for greater clinical effects as well as more adverse effects

  33. CYP450 • The majority of hepatic metabolism occurs via the CYP450 system, comprised of more than 30 isoenzymes • It has been theorized that sex-related pharmacokinetic differences may be due to hormonal influences causing differential expression and altered activity of multiple isoforms

  34. CYP System and Sex Effects

  35. CYP450 • There is conflicting evidence for many of these agents • The data presented here are consensus data from various sources • CYP3A4 accounts for about 60% of all metabolic activities due to the CYP450 sytem • It also accounts for the most important sex-related differences noted in drug metabolism

  36. CYP450 • This particular isozyme is influenced by sex as well as age • With 20-40% higher CYP3A4 activity in young women when compared to both men and elderly women • Thus young women will metabolize certain medications more quickly, leading to lower concentrations of the medication and less efficacy

  37. CYP450 • Women have greater CYP2C19 activity than men, leading to faster metabolism and lower drug concentrations • Although this enzyme’s activity may fluctuate in the presence of other medications • Studies in both Sweden and the Netherlands found CYP2C19 activity to be 40% greater in men and 61% lower in women taking OCPs

  38. CYP450 • The CYP2D6 isoform metabolizes many drugs • It is commonly implicated in drug-drug interactions • Men tend to have higher enzyme expression • Pregnancy increases the activity of CYP2D6 • Thus, it may be under the influence of sex steroids, although there has been no supporting data of their role in changing drug concentrations

  39. Elimination • Drug elimination takes place for the most part via hepatic, renal, and pulmonary routes • Hepatic clearance of medications depends on both blood flow and intrinsic hepatic enzyme activity • Women have lower hepatic blood flow; thus, they have less medication made available for elimination by the liver

  40. Elimination • Of particular concern is the role of hormones in expression of P glycoproteins • These proteins regulate biliary excretion of drugs • P glycoproteins have been found to be 2.4-fold lower in women when compared to men • Women also have lower rates of glomerular filtration • Adjustments for renal clearance may reduce the adverse effects of renally excreted drugs

  41. Drug Transporters • Molecular drug transporters have been found to alter pharmacokinetics by influencing absorption, distribution, and excretion • The most commonly recognized drug transporter is p-glycoprotein • Studies looking at sex differences have found that women express 1/3 to 1/2 the hepatic protein concentrations that men express

  42. Drug Transporters • Reduced expression affects several steps in medication metabolism • Low levels of p-glycoprotein affect absorption by leading to reduced gastrointestinal transit time • Thus decreased intestinal wall metabolism via CYP3A4 and increased concentration and effect • Decreased p-glycoprotein in the liver leads to increased CYP3A4 metabolism • As noted by the metabolsim of both alfentanil and nifedipine

  43. Pharmacodynamics • Refers to the effects a medication has on the individual, including both the clinical effect and adverse effects • Unfortunately, there is limited data on sex-related effects on pharmacodynamics • Women are more likely to take medications when compared to men • Available data indicate that this may be due to sex-related differences in drug responses

  44. Pharmacodynamics • Antipsychotics have been reported to create a more pronounced response in women • This effect may be due to hormonal influences leading to higher dopamine uptake in the striatum • Women are more likely to respond to selective serotonin reuptake inhibitors (SSRIs), while men are more likely to respond to tricyclic antidepressants

  45. Pharmacodynamics • Illicit drugs also appear to have sex-related differences • Women are more responsive to both cocaine and methylphenidate, • but less responsive to amphetamines • In addition, the subjective effects of cocaine and amphetamine are reduced by hormonal influences during the luteal phase of the menstrual cycle

  46. Pharmacodynamics • Women are less susceptible to toxicity from methamphetamine • Women have even demonstrated fewer EEG changes when compared to men • It is clear that women have a higher rate and more severe adverse drug reactions • Whether these are primarily pharmacokinetic or pharmacodynamic effects or a combination of both is not yet clear

  47. Site of Action Effects • Although limited data are available, some site of action effects appear to be enhanced in women: • Hemorrhagic consequences with anticoagulation and thrombolytics • Diuretic-induced electrolyte abnormalities • Myopathy in the setting of statins • Cough from angiotensin converting enzyme (ACE) inhibitor therapy

  48. QTc Effects • Prolongation of the QT interval has been shown to increase the risk of sudden tachydysrhythmias, specifically polymorphic ventricular tachycardia (torsades de pointes) • Women account for more than 70% of all cases of drug-induced polymorphic ventricular tachycardia • Multiple medications have been shown to prolong the QT interval

  49. QTc Effects • QT interval length is directly proportional to the flow of potassium through potassium channels • Cellular production of potassium channels is enhanced by testosterone • When boys’ testosterone concentration increases at puberty, the QTc (rate corrected QT) shortens due to increased production of potassium channels

  50. QTc Effects • Conversely, QTc gradually increases in women • QTc durations in men and women become similar as testosterone concentrations in men decrease with age • Decreased testosterone in women also enhances the effect of QT-prolonging drugs • For example, women may develop a proportionately longer increase in QT compared to men when given an identical per weight dose of a QT-prolonging medication

More Related